[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
Contact us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Last site contents
:: Editorial Board
:: About Iranian Journal of Endocrinology and Metabolism
:: Volume 7, Issue 2 (6-2005) ::
2005, 7(2): 135-142 Back to browse issues page
The effect of HMG-CoA reductase inhibitor (lovastatin) on bone mineral density (BMD) in postmenopausal women with type 2 diabetes
H Safaei , M Amini , M Janghorbani
, emrc@mui.ac.ir
Abstract:   (25746 Views)
Introduction: Decreased rates of bone fracture have been reported in hypercholesterolemic patients treated with statin compounds. Considering the higher prevalence of bone fractures in diabetic patients compared to non-diabetics, this study was performed to determine the effect of lovastatin on the bone mineral density (BMD) of postmenopausal women with type 2 diabetes. Materials & Methods: In this clinical trial study, 60 postmenopausal womean with type 2 diabetes were divided into 2 groups (with and without hypercholesterolemia) matched for age, diabetes duration, BMI and duration of menopause. Hypercholesterolemic subjects were treated with lovastatin for 18 months. Using DXA, bone densitometries was performed in all patients before and at the end of the study and the results were compared. Results: Total hip and lumbar spine BMD significantly increased in the treated group (p<0.01). In control subjects BMD decreased in total hip and increased in lumbar spine, but not significantly. Percentage changes of BMD in the femoral neck, wards triangle, trochanter, total hip and lumbar spine were 3.5% ,15.7% , 1.7%,3.29% and 3.2% respectively in the treated group as compared to -2.54% , 3% ,-2.2% , -2.2% and 1.1% in control subjects, respectively. Conclusion: According to our findings, lovastatin can increase the BMD in postmenopausal women with type 2 diabetes. It seems that these agents may slow the process of osteoporosis or stop its progression, especially in hypercholesterolemic patients.
Keywords: Endocrine & Metabolism Research Center, Isfahan University of Medical Science, Isfahan, Iran
Full-Text [PDF 349 kb]   (3032 Downloads)    
Type of Study: Original | Subject: Endocrinology
Received: 2006/11/16 | Published: 2005/06/15
Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Safaei H, Amini M, Janghorbani M. The effect of HMG-CoA reductase inhibitor (lovastatin) on bone mineral density (BMD) in postmenopausal women with type 2 diabetes. Iranian Journal of Endocrinology and Metabolism 2005; 7 (2) :135-142
URL: http://ijem.sbmu.ac.ir/article-1-113-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 7, Issue 2 (6-2005) Back to browse issues page
مجله ی غدد درون‌ریز و متابولیسم ایران، دو ماهنامه  پژوهشی مرکز تحقیقات غدد درون‌ریز و متابولیسم، Iranian Journal of Endocrinology and Metabolism
Persian site map - English site map - Created in 0.06 seconds with 38 queries by YEKTAWEB 4691